Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma
Journal of Hematology · 2025-06 · 14 (3) · 146-151
DOI: 10.14740/jh2046 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Hematology, 2025-06. Verfasst von Baldeep Wirk und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cellular Immunotherapies and Transplant Program, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23219, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cellular Immunotherapies and Transplant Program, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23219, USA.
- Department of Radiology, Virginia Commonwealth University, Richmond, VA 23219, USA.
Zitieren
APA
Wirk, B., & Lim, J. (2025). Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma. Journal of Hematology, 14(3), 146-151. https://doi.org/10.14740/jh2046
Vancouver
Wirk B, Lim J. Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma. Journal of Hematology. 2025;14(3):146-151. doi:10.14740/jh2046
BibTeX
@article{Wirk2025,
author = {Wirk, Baldeep and Lim, Jin},
title = {Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma},
journal = {Journal of Hematology},
year = {2025},
volume = {14},
number = {3},
pages = {146--151},
doi = {10.14740/jh2046}
}
EUVIMED